Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Synairgen (SYNG)

London
Currency in GBP
Disclaimer
6.24
0.00(0.00%)
Real-time Data

SYNG Price Commentary

https://www.marketwatch.com/story/synairgen-shares-rise-on-positive-analysis-of-phase-3-covid-19-treatment-trial-271652687610
https://www.synairgen.com/media/synairgen-presents-at-ats-2022
Presenting to the ATS today, also rumours for a takeover…
Though brief, interesting read and move in the right direction: https://www.synairgen.com/media/presentation-at-eccmid
New promosing drug on the market in the name of VERU. Short Synairgen under 10
Polygon position, Polygon Global Partners LLP 50,927,428 Ordinary shares (25.3%). Major shareholder, in at different levels, will they sell out, NOPE
Why shouldnt there be a recovery? Polygon still have a major position and speaks volumes, IMO. On unpteen occasions i have said the company are not just covid related researches but also many lung related conditions are u der the microscope. Defo HOLD
recovery?
Indeed, oops
oops
And now we can expect an announcement... the Phase 3 trials are to continue!!!
IMO, much hope prevails for this stock, emailed and received an informative response from Brooke Clarke, defo HOLD
The Company also announced that in vitro studies conducted at Viroclinics-DDLin the Netherlands have shown that SNG001 has potent antiviral activityagainst SARS-CoV-2 Delta and Omicron variants at concentrations that arereadily achievable following inhaled delivery of interferon beta.
Polygon updated hold: https://www.synairgen.com/media/2022-02-24-holdings-in-company
Thank you fellas! Good info.
So, a RNS from Polygon, affirming they have 22%+Good news.
Harry, Trouble is that small investors viewed and took large positions in the company based purely on their COVID inhaler study. Synairgen as we all know are studying and producing, through the trials, inhalers etc for all types of lung diseases and includes COPD.Yes the announcement that their Sprinter/Phase 3 trials had not delivered the desired or anticipated outcome, nonetheless they will review the data and probably will revisit and deliver an enhanced medication, maybe??The sell off was obviously based on the results but also “many” traders had stop loss positions which were automatically triggered and as consequence of that it pushed the SP sliding. I have been watching the daily trading activity this week and there has been high levels of buyingIf you, like me, had relatively small positions the opportunity to buy the lows to average up the downside seemed the prudent action to take. Clearly this is longer term than we expected but positivity needs to prevail
I concur but bow to your more detailed understanding.Having 'followed' SNG for some time I was on the cusp when the results arrived.My shock was with the results not with the cruel loss of money ( have experienced that a couple of times).I read with undisguised anger at some posters on LSE and advfn who take pleasure in misfortune of others. I digress.So I'm new as in a new investor....the risk may be greater actually but certainly worth it I suspect.Kind regards Sir
Gradual rise over the next week or two, perhaps to 37-42.Bottom line is c25.5pConfident that cash ( half of mcap) and COPD study etc will permit this rise.After that?Takeover? No idea.
What are peoples thoughts on what will happen now?
Apologies, hit button too quickly
I absolutely concur with these comments: “Seriously guys/gals nobody sell at this price it's an absolute joke.....still COPD and asthma in play! Horrendous over reaction!!!!”
😔
Phase 3 Sprinter Trials dids not give the expected ‘FULL” results. Note this is a knee jerk reaction to the news
Apparently a mistake and almost immediately rectified.14-Feb-22t13:09:48t108.75t-7,500tUnknown*t-8,156tO 14-Feb-22t13:09:48t108.75t7,500tSell*t8,156 O
what happened earlier? Big drop and then right back up?
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.